Skip to main content
. 2021 Apr 13;13(8):1845. doi: 10.3390/cancers13081845

Figure 2.

Figure 2

Murlentamab opsonization of SKOV3-R2+ increases macrophage anti-tumoral activity and antibody-dependent cell-mediated cytotoxicity (ADCC) killing. SKOV3-R2+ ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (tumor-associated macrophages (TAMs)). (A) Opsonized-SKOV3-R2+ cell number was determined by flow cytometry after one and two days of co-culture with M0 or TAMs. * p < 0.05; ** p < 0.01 compared 3C23K-FcKO vs. murlentamab at a given time (B) ADCC was performed after 4 h of co-culture between SKOV3-R2+ cells and M0 or TAMs. Data shown (mean ± SEM) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.